Active substance
Results for the substance ombitasvir+paritaprevir+ritonavir
1 result
About this active substance
This combination of ombitasvir, paritaprevir, and ritonavir is used for the treatment of chronic hepatitis C, particularly in patients with genotypes 1 and 4 of the virus. Ombitasvir inhibits the NS5A protein, paritaprevir inhibits the NS3/4A protease, and ritonavir is used to boost paritaprevir levels in the body.
The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and complete the full course of treatment to prevent recurrence of the infection.
Patients should be aware of potential side effects, such as nausea, fatigue, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, fatigue, insomnia, and elevated liver enzymes. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.
The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and complete the full course of treatment to prevent recurrence of the infection.
Patients should be aware of potential side effects, such as nausea, fatigue, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, fatigue, insomnia, and elevated liver enzymes. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.